New Novozymes President & CEO

The Board of Directors of Novozymes has appointed Peder Holk Nielsen as President and Chief Executive Officer with effect from April 1, 2013.

Peder Holk Nielsen, 56, is currently serving as Executive Vice President and head of Enzyme Business, a position he has held since 2007. Prior to this, Nielsen’s career spans management positions in Novozymes and Novo Industri/Novo Nordisk across business development, R&D, quality management and sales & marketing.

He holds a M.Sc. and Ph.D. in Chemical Engineering from Technical University of Denmark and a B.Com. in International Business Management from Copenhagen Business School. He is also member of the Board of Directors of Hempel A/S and of LEO Pharma A/S.

Peder Holk Nielsen will succeed Steen Riisgaard as President and Chief Executive Officer who steps down after 12 years at the company’s top post and 33 years in Novozymes and Novo Industri/Novo Nordisk.

As of April 1, 2013 Novozymes executive management will organize into a functional structure with all current Executive Vice Presidents and joined by Andrew Fordyce. Today VP of Sales and Customer Solutions, Andrew Fordyce, 49, has been with the company since 1993, holding positions in commercial operations, R&D and production in Denmark, Switzerland and the US.